Jing L. Marantz Sells 5,655 Shares of Scholar Rock Holding Co. (NASDAQ:SRRK) Stock

Scholar Rock Holding Co. (NASDAQ:SRRK) insider Jing L. Marantz sold 5,655 shares of the firm’s stock in a transaction that occurred on Thursday, January 16th. The shares were sold at an average price of $44.20, for a total transaction of $249,951.00. Following the completion of the sale, the insider now owns 67,200 shares in the company, valued at $2,970,240. This represents a 7.76 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Scholar Rock Stock Performance

Shares of Scholar Rock stock opened at $46.73 on Thursday. The company has a market cap of $4.37 billion, a P/E ratio of -19.89 and a beta of 0.52. The company has a current ratio of 3.88, a quick ratio of 3.88 and a debt-to-equity ratio of 0.63. The business has a 50-day moving average price of $40.33 and a two-hundred day moving average price of $23.75. Scholar Rock Holding Co. has a 1-year low of $6.76 and a 1-year high of $46.81.

Wall Street Analyst Weigh In

SRRK has been the topic of several recent research reports. Piper Sandler raised their price objective on Scholar Rock from $28.00 to $42.00 and gave the company an “overweight” rating in a report on Tuesday, October 15th. Truist Financial boosted their price target on Scholar Rock from $36.00 to $45.00 and gave the stock a “buy” rating in a report on Monday, November 25th. HC Wainwright raised their price objective on shares of Scholar Rock from $40.00 to $50.00 and gave the company a “buy” rating in a report on Tuesday, November 26th. BMO Capital Markets boosted their target price on shares of Scholar Rock from $34.00 to $38.00 and gave the stock an “outperform” rating in a report on Friday, October 11th. Finally, JPMorgan Chase & Co. raised their target price on Scholar Rock from $18.00 to $31.00 and gave the stock an “overweight” rating in a research report on Monday, October 14th. Six investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Buy” and an average target price of $40.43.

Institutional Investors Weigh In On Scholar Rock

A number of hedge funds have recently added to or reduced their stakes in the business. KBC Group NV acquired a new stake in shares of Scholar Rock during the 4th quarter worth approximately $131,000. Nisa Investment Advisors LLC grew its holdings in Scholar Rock by 1,321.8% in the fourth quarter. Nisa Investment Advisors LLC now owns 1,109 shares of the company’s stock worth $48,000 after purchasing an additional 1,031 shares during the period. Hamilton Lane Advisors LLC bought a new stake in Scholar Rock in the fourth quarter valued at $1,274,000. GAMMA Investing LLC raised its holdings in shares of Scholar Rock by 51.8% during the fourth quarter. GAMMA Investing LLC now owns 788 shares of the company’s stock valued at $34,000 after purchasing an additional 269 shares during the period. Finally, JPMorgan Chase & Co. boosted its position in shares of Scholar Rock by 1.0% during the 3rd quarter. JPMorgan Chase & Co. now owns 38,726 shares of the company’s stock worth $310,000 after purchasing an additional 379 shares in the last quarter. 91.08% of the stock is currently owned by institutional investors.

Scholar Rock Company Profile

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies.